DTIL Quote, Financials, Valuation and Earnings

Assembly Biosciences has a net margin of -2851.56% compared to Precision BioSciences's net margin of -140.44%. Precision BioSciences's return on equity of 19.19% beat Assembly Biosciences's return on equity of -115.86%.

Precision BioSciences has a consensus price target of $33.60, signalling upside risk potential of 622.58%. On the other hand Assembly Biosciences has an analysts' consensus of -- which suggests that it could grow by 134.17%. Given that Precision BioSciences has higher upside potential than Assembly Biosciences, analysts believe Precision BioSciences is more attractive than Assembly Biosciences.

Precision BioSciences has a beta of 1.408, which suggesting that the stock is 40.772% more volatile than S&P 500. In comparison Assembly Biosciences has a beta of 0.587, suggesting its less volatile than the S&P 500 by 41.316%.

Precision BioSciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Assembly Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Precision BioSciences pays -- of its earnings as a dividend. Assembly Biosciences pays out -- of its earnings as a dividend.

Precision BioSciences quarterly revenues are $576K, which are smaller than Assembly Biosciences quarterly revenues of $6.8M. Precision BioSciences's net income of -$16.4M is lower than Assembly Biosciences's net income of -$9.6M. Notably, Precision BioSciences's price-to-earnings ratio is 77.50x while Assembly Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Precision BioSciences is 0.36x versus 3.05x for Assembly Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -2851.56% compared to Precision BioSciences's net margin of 25.23%. Precision BioSciences's return on equity of 19.19% beat Pfizer's return on equity of 4.63%.

Precision BioSciences has a consensus price target of $33.60, signalling upside risk potential of 622.58%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 19.7%. Given that Precision BioSciences has higher upside potential than Pfizer, analysts believe Precision BioSciences is more attractive than Pfizer.

Precision BioSciences has a beta of 1.408, which suggesting that the stock is 40.772% more volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

Precision BioSciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.31% to investors and pays a quarterly dividend of $0.42 per share. Precision BioSciences pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

Precision BioSciences quarterly revenues are $576K, which are smaller than Pfizer quarterly revenues of $17.7B. Precision BioSciences's net income of -$16.4M is lower than Pfizer's net income of $4.5B. Notably, Precision BioSciences's price-to-earnings ratio is 77.50x while Pfizer's PE ratio is 35.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Precision BioSciences is 0.36x versus 2.55x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Protagonist Therapeutics has a net margin of -2851.56% compared to Precision BioSciences's net margin of -710.37%. Precision BioSciences's return on equity of 19.19% beat Protagonist Therapeutics's return on equity of 37.59%.

Precision BioSciences has a consensus price target of $33.60, signalling upside risk potential of 622.58%. On the other hand Protagonist Therapeutics has an analysts' consensus of -- which suggests that it could grow by 47.59%. Given that Precision BioSciences has higher upside potential than Protagonist Therapeutics, analysts believe Precision BioSciences is more attractive than Protagonist Therapeutics.

Precision BioSciences has a beta of 1.408, which suggesting that the stock is 40.772% more volatile than S&P 500. In comparison Protagonist Therapeutics has a beta of 2.178, suggesting its more volatile than the S&P 500 by 117.841%.

Precision BioSciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protagonist Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Precision BioSciences pays -- of its earnings as a dividend. Protagonist Therapeutics pays out -- of its earnings as a dividend.

Precision BioSciences quarterly revenues are $576K, which are smaller than Protagonist Therapeutics quarterly revenues of $4.7M. Precision BioSciences's net income of -$16.4M is higher than Protagonist Therapeutics's net income of -$33.2M. Notably, Precision BioSciences's price-to-earnings ratio is 77.50x while Protagonist Therapeutics's PE ratio is 14.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Precision BioSciences is 0.36x versus 7.43x for Protagonist Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Entrada Therapeutics has a net margin of -2851.56% compared to Precision BioSciences's net margin of -71.7%. Precision BioSciences's return on equity of 19.19% beat Entrada Therapeutics's return on equity of 17.06%.

Precision BioSciences has a consensus price target of $33.60, signalling upside risk potential of 622.58%. On the other hand Entrada Therapeutics has an analysts' consensus of -- which suggests that it could grow by 51.8%. Given that Precision BioSciences has higher upside potential than Entrada Therapeutics, analysts believe Precision BioSciences is more attractive than Entrada Therapeutics.

Precision BioSciences has a beta of 1.408, which suggesting that the stock is 40.772% more volatile than S&P 500. In comparison Entrada Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Precision BioSciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Entrada Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Precision BioSciences pays -- of its earnings as a dividend. Entrada Therapeutics pays out -- of its earnings as a dividend.

Precision BioSciences quarterly revenues are $576K, which are smaller than Entrada Therapeutics quarterly revenues of $19.6M. Precision BioSciences's net income of -$16.4M is lower than Entrada Therapeutics's net income of -$14M. Notably, Precision BioSciences's price-to-earnings ratio is 77.50x while Entrada Therapeutics's PE ratio is 10.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Precision BioSciences is 0.36x versus 2.92x for Entrada Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.